This Viewpoint discusses ways that artificial intelligence (AI) may improve the productivity of primary care physicians with easier and more accurate use of AI-
Overcome Vaccine Hesitancy Among PLWH by Acknowledging the History of AZT thebody.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thebody.com Daily Mail and Mail on Sunday newspapers.
Commentary: How Operation Warp Speed created winning vaccines Toggle share menu
Advertisement
Commentary: How Operation Warp Speed created winning vaccines Industrial policy and state direction had little to do with the COVID-19 vaccines success, say Deirdre Nansen McCloskey and Alberto Mingardi.
The COVID-19 vaccine being administered at Kolam Ayer Community Club, Singapore, on Apr 21, 2021. (Photo: Marcus Mark Ramos)
19 May 2021 06:10AM) Share this content
Bookmark
CHICAGO, Illinois: As COVID-19 vaccines are rolled out, only some parts of the world can breathe a sigh of relief.
In most of the world, scarce or nonexistent doses recall the product shortages in communist Eastern Europe in the 1980s.
It took less than a year for researchers to develop a vaccine against Covid-19. The search for an HIV vaccine began almost 40 years ago.
The unprecedented pace at which the Covid-19 jabs were developed and the scientific breakthroughs they required have re-energised those efforts to develop an HIV vaccine. But they have also raised critical questions about what could have been if the search for an HIV vaccine had met with the same resources and political will as the coronavirus pandemic.
Consider that between 2000 and 2019, $15.3bn was spent on the research and development of HIV vaccines, according to the Resource Tracking for HIV Research and Development Working Group. According to an analysis by Devex, by August 2020, less than a year into the pandemic, more than $39.5bn was slated for spending on Covid-19 vaccine research and distribution,
Moderna s partnership will build on a new and unproven vaccine approach
William Schief, an immunology professor at Scripps Research and vaccine design director of the International AIDS Vaccine Initiative, presented Moderna s investors with unpublished data from an HIV vaccine trial presented at a virtual AIDS research conference in February.
The trial, which started in 2018, was conducted with 48 HIV-negative adults, and will serve as preliminary basis off which Moderna and its collaborators will further study and test a vaccine approach targeting broadly neutralizing antibodies. Subjects were given either a low or high dose of the protein-based vaccine candidate, which was designed to activate certain naive B cells of the immune system.